1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68B1E9F50B20DECD8002585DC003E223F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-top-management-tactics-long-term-strategies-senior-biopharma-executives-steering-through-covid-19-beyond?opendocument
18
19opendocument
203.236.55.22
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Business Operations Strategic Planning and Management

Top Management Tactics & Long-Term Strategies for Senior Biopharma Executives Steering through COVID-19 and Beyond

ID: 5635


Features:

13 Info Graphics

25 Data Graphics

870+ Metrics

22 Narratives


Pages/Slides: 48


Published: 2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Top Management Tactics & Long-Term Strategies for Senior Biopharma Executives Steering through COVID-19 and Beyond”

Biopharma organizations - and the strategies of their senior leaders - must evolve to meet short-term threats and long-term challenges arising out of the COVID-19 health and economic crisis.

Best Practices, LLC conducted this benchmarking research to help senior biopharma executives audit the management tactics, top objectives, critical decision factors, investment patterns, cost control approaches, and future strategies being employed by their industry peers.

This study will help biopharma leaders make essential, evidence-based decisions to secure the health of their employees and the success of their organizations.

The study also analyzes the priorities and potential blindspots of both C-Suite Executives versus Function-Level Heads to ensure better communication, integrated strategy and optimal performance throughout all organizational levels.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Consulting; Medical Device; Health Care; Technology; Clinical Research; Laboratories; Science


Companies Profiled:
Almirall; Apellis Pharmaceuticals; Astellas; Biofrontera; Biogen; Boehringer Ingelheim; Ferozsons Laboratories Limited; Halloran Consulting Group; Helsinn; Joerns Healthcare; Kala Pharmaceuticals; Inc.; Kaleo; Medacta USA; MEDiSTRAVA; Mint Pharmaceuticals Inc.; Mirador Analytics Ltd.; Monebo Technologies; Nevakar; Novartis; Nuvisan; Pfizer; Purdue Pharma; Samumed; Sandoz; Sanofi; Santen; SomaGenics Inc; Syneos Health; Takeda Pharmaceuticals; The Medical Affairs Company; Thermo Fisher Scientific; UCB Pharma; Vertex Pharmaceuticals; XG Sciences; Inc

Study Snapshot

Best Practices, LLC engaged 40 executives from 34 life science companies in this research through a benchmarking survey. Nearly 60% of surveyed participants served at the C-suite, President or Vice President level.

Key topics covered in this study include:

  • Top management objectives & effective day-to-day practices
  • Key financial & operational decisions being made
  • Key lessons & long-term opportunities
  • Management perspectives of Senior Executives vs. Function Heads


Key Findings

Select key insights uncovered from this research are noted below. Detailed findings are available in the full study.

  • Top short-term priorities:

    • Health: Ensuring employee and patient health are top short-term goals
    • Ops & finance: Operations and financial considerations are 3rd and 4th among 12 surveyed senior-executive objectives
    • Digital transformation comes next, superseding immediate business results, external engagement strategy, innovation, alliances and regulatory

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.